The U.S. Food and Drug Administration (FDA) recently convened a committee of independent advisors to review a cardiac device made by Abbott but failed to disclose that most of them had financial ties to the company.
According to the Open Payments database, 10 of the 14 voting members on the FDA’s advisory panel tasked with reviewing the clinical data for Abbott’s heart device and voting on information related to its premarket approval application received a total of roughly $650,000 between 2016 and 2022.
